|

Lu-PSMA-617 Clinical Trials

3 actively recruiting trials across 1 location

▲ +1 trial since May 2026

Also known as: Pluvicto

Pipeline

Phase 2: 2Phase 1/2: 1

Top Sponsors

  • Melissa Lumish1
  • Case Comprehensive Cancer Center1
  • Angela Y. Jia, MD PhD1

Indications

  • Cancer3
  • Liver Disease1
  • Malignant Neoplasm of Prostate1
  • Metastatic Castration-resistant Prostate Cancer1
  • Locally Advanced Prostate Cancer1

Cleveland, Ohio3 trials

68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)

Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center, Seidman Cancer Center

Phase 2
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer Center

Phase 2
STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer

University Hospitals Cleveland Medical Center Seidman Cancer Center, Case Comprehensive Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.